Intentar ORO - Gratis
Pharma scions take the reins
Mint Hyderabad
|June 02, 2025
Vidhi Shanghvi has been named director at Sun Pharma, while Aman Mehta will become MD at Torrent Pharma
Some of India's largest pharmaceutical firms, including Sun Pharmaceutical Industries Ltd and Torrent Pharmaceuticals Ltd, are priming the next generation of their promoter families to take the reins.
On 20 May, Torrent Pharma announced the appointment of Aman Mehta (33), son of chairman Samir Mehta and a third-generation member of the Torrent Group's founder family, as managing director effective 1 August. The company said in a press statement that the appointment was part of "our long-term strategic vision and succession planning".
The same week, Sun Pharma announced the appointment of Vidhi Shanghvi, daughter of founder and managing director Dilip Shanghvi, as a whole time director. A few months ago, Sun Pharma elevated Aalok Shanghvi (40), Dilip Shanghvi's son, as chief operating officer.
Other pharma companies like Lupin Ltd too have seen the next generation of their promoter families take charge in recent years. With the Indian pharmaceutical industry growing at a significant rate, the top companies in the sector are being closely watched for the evolution they are undertaking.
Experts believe such successions must be planned with foresight, factoring in ideal transition times, grooming, and the role of other veteran executives in shaping up the incoming leaders.
"If one has to think about a template, I think a good template is one where there is a fair bit of overlap between the senior generation and the next generation. And the next generation gets a good chance to actually experience different parts of the business," said Amit Misra, managing director with consultancy firm Alvarez and Marsal's healthcare and life sciences practice in Mumbai.
Aman Mehta, the newly appointed managing director of Torrent Pharma, is a whole-time director at Torrent Pharma. He was appointed as a director in 2022 and has been primarily involved with Torrent Pharma's India business, the company's largest revenue contributor.
Esta historia es de la edición June 02, 2025 de Mint Hyderabad.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Mint Hyderabad
Mint Hyderabad
Dalmia Bharat’s capacity drive promising, but risks remain
Dalmia Bharat Ltd's focus on capacity expansion could help it regain lost ground.
1 mins
October 24, 2025
Mint Hyderabad
Farm insurance: Time for climate-linked bulk payouts
India's agriculture sector employs nearly half of its population and accounts for about 18% of the country's gross domestic product (GDP).
3 mins
October 24, 2025
Mint Hyderabad
HUL bets on price cuts for sales after GST disruption
Wait for lower prices dampens sales; HUL expects volumes to rise from November
1 mins
October 24, 2025
Mint Hyderabad
Kenya on a budget: Three friends—and a dream safari
Exploring wildlife, secret beaches from Masai Mara to Diani Coast without breaking the bank
4 mins
October 24, 2025
Mint Hyderabad
SMALL STAYS, BIG MARGINS: INSIDE MMT'S PIVOT
MakeMyTrip is leaning on 'constructive paranoia' to counter rivals and the threat of direct booking
7 mins
October 24, 2025
Mint Hyderabad
India plans strict rules for gene therapy
India plans to bring the new generation of medical treatments involving gene and stem cell therapies under strict governmental control as the market for such treatments grows.
1 mins
October 24, 2025
Mint Hyderabad
Auto firms want clean energy to fuel 50% of cars sold by '30
It will require them to increase contribution of clean vehicles ten-fold over the next 5 years
3 mins
October 24, 2025
Mint Hyderabad
India stares at $2.7 bn hit as US sanctions Russian oil cos
Sanctions on Rosneft, Lukoil are likely to force Indian refiners to buy oil from other sources
2 mins
October 24, 2025
Mint Hyderabad
Companies Act changes soon
take a view on it,\" said the person.
1 mins
October 24, 2025
Mint Hyderabad
'My gold and silver are for my children'
Known for his contrarian view and focus on commodities like gold and silver, veteran investor Jim Rogers is cautious and a bit worried.
3 mins
October 24, 2025
Listen
Translate
Change font size

